Comparison · NCT00574249-sae
Adalimumab + Placebo vs Adalimumab + Calcipotriol/Betamethasone: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Adalimumab + Placebo vs Adalimumab + Calcipotriol/Betamethasone: serious adverse events. Trial comparisons, record NCT00574249-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00574249-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0412 | 0.0251 | 0.0669 | wilson | |
| Risk in group 2 | 0.0437 | 0.0271 | 0.0698 | wilson | |
| Risk difference, group 1 minus group 2 | -0.00251 | -0.0332 | 0.0281 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.943 | 0.473 | 1.88 | log | |
| Odds ratio, group 1 over group 2 | 0.94 | 0.458 | 1.93 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Adalimumab + Placebo than on Adalimumab + Calcipotriol/Betamethasone | 399 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Adalimumab + Placebo | adalimumab + placebo (vehicle ointment): subcutaneous injection using prefilled pen/syringe, solution containing 40 mg adalimumab in 0.8 milliliters; 2 injections given at Baseline (Day 1) then one injection every other week from Week 1 through Week 15 | 15 | 364 | EG000 |
| Group 2 | Adalimumab + Calcipotriol/Betamethasone | adalimumab + calcipotriol/betamethasone ointment | 16 | 366 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Overall study
Source ClinicalTrials.gov
Trial
- Title
- Adalimumab in Combination With Topical Treatment (Calcipotriol/Betamethasone) in Subjects With Moderate to Severe Psoriasis and Insufficient Response to Classic Systemic Treatment
- NCT number
- NCT00574249
- Phases
- PHASE3
- Conditions
- Chronic Plaque Psoriasis
- Interventions
- adalimumab, Calcipotriol/Betamethasone Ointment, placebo (vehicle ointment)
- Lead sponsor
- Abbott
- Results first posted
- 2010-01-18
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00574249?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00574249-sae